© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 23, 2022
CheckMate 9X8 trial results indicate a progression-free survival improvement with nivolumab that was not statistically significant.
January 22, 2022
Promising study results support continued research of T-DXd in patients with HER2-positive mCRC while the risk of potential ILD/pneumonitis requires monitoring.
January 19, 2022
Retrospective data show that only 24% of patients treated with immune checkpoint inhibitors required immunosuppression while the rest recovered over time.
January 14, 2022
Phase 3 study findings show that paclitaxel combined carboplatin stands up to the combination of paclitaxel and ifosfamide for the treatment of patients with uterine carcinosarcoma.
January 05, 2022
Phase 1b data indicate that pembrolizumab in combination with pepinemab is safe for the frontline treatment of advanced, recurrent, or metastatic head and neck squamous cell carcinoma.
December 21, 2021